Table 1.

Characteristics of venous thromboembolism patients by anticoagulant initially prescribed, MarketScan databases, 2017

	Warfarin (N = 2172)	Rivaroxaban (N = 4773)	Apixaban (N = 4128)	P value
				Rivaroxaban vs. warfarin	Apixaban vs. warfarin	Apixaban vs. rivaroxaban
Age, y	57.2 ± 16.4	53.4 ± 14.8	56.8 ± 15.9	<0.00	0.42	<0.00
Female, %	49.9	49.7	50.5	0.89	0.63	0.43
Comorbidities, %
Hypertension	60.5	47.4	59.1	<0.00	0.29	<0.00
Diabetes mellitus	24.3	16.9	22.1	<0.00	0.05	<0.00
Myocardial infarction	9.6	4.3	6.5	<0.00	<0.00	<0.00
Heart failure	18.1	7.9	13.4	<0.00	<0.00	<0.00
Atrial fibrillation	9.3	4.6	8.9	<0.00	0.61	<0.00
Ischemic stroke	3.9	2.0	3.3	<0.00	0.28	<0.00
Peripheral artery disease	15.3	8.0	12.7	<0.00	0.004	<0.00
Dementia	4.1	1.6	3.2	<0.00	0.08	<0.00
Chronic pulmonary disease	23.2	19.8	22.1	0.001	0.36	0.007
Renal disease	15.1	5.3	10.4	<0.00	<0.00	<0.00
Liver disease	8.6	6.4	8.0	0.001	0.36	0.01
Depression	20.2	16.0	17.7	<0.00	0.02	0.03
Hematologic disorders	15.2	8.7	10.2	<0.00	<0.00	0.02
Alcohol abuse	3.0	2.4	2.6	0.16	0.48	0.41
Medications, %
Antiplatelets	6.5	3.2	5.5	<0.00	0.10	<0.00
ACE inhibitors	21.1	16.7	21.4	<0.00	0.81	<0.00
Angiotensin receptor blockers	14.3	12.1	15.0	0.01	0.47	<0.0001
Beta‐blockers	27.3	17.9	25.2	<0.00	0.08	<0.00
Calcium channel blockers	18.1	13.6	18.6	<0.00	0.59	<0.00
Statins	30.0	23.7	29.3	<0.00	0.60	<0.00
Diabetes mellitus medications	6.3	3.8	4.8	<0.00	0.02	0.01
SSRIs	27.1	24.2	26.0	0.01	0.36	0.05

ACE, angiotensin‐converting enzyme; SSRI, selective serotonin reuptake inhibitors.

Values correspond to mean ± standard deviation or percentage.